{"id":"pred-meth","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Immunosuppression-related complications"}]},"_chembl":{"chemblId":"CHEMBL49073","moleculeType":"Small molecule","molecularWeight":"320.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Prednisolone reduces inflammation by suppressing immune cell activation and cytokine production. Methotrexate inhibits dihydrofolate reductase and has immunosuppressive effects through multiple pathways including adenosine release. Together, they provide synergistic anti-inflammatory and immunosuppressive effects for autoimmune and inflammatory conditions.","oneSentence":"A combination of prednisolone (a corticosteroid) and methotrexate (an immunosuppressant/antimetabolite) that suppresses inflammation and immune activity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:51:50.944Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Autoimmune and inflammatory disorders (specific indication not publicly detailed for this Phase 3 trial)"}]},"trialDetails":[{"nctId":"NCT01724268","phase":"PHASE3","title":"Corticosteroids and Anti TNF in Methotrexate Inadequate Responder Rheumatoid Arthritis Patient","status":"UNKNOWN","sponsor":"Hamad Medical Corporation","startDate":"2012-05","conditions":"RHEUMATOID ARTHRITIS","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prednisolone","Methotrexate"],"phase":"phase_3","status":"active","brandName":"Pred + Meth","genericName":"Pred + Meth","companyName":"Hamad Medical Corporation","companyId":"hamad-medical-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A combination of prednisolone (a corticosteroid) and methotrexate (an immunosuppressant/antimetabolite) that suppresses inflammation and immune activity. Used for Autoimmune and inflammatory disorders (specific indication not publicly detailed for this Phase 3 trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}